Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | MGMT | P16455 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30152317 | 1.00 | TP53 (0.47) | TP53MEN1KMT2AMAPTEGFR | |
| SCHEMBL8808411 | 0.86 | MEN1 (0.61) | MEN1KMT2AMAPTMAOBVCAM1 | |
| SCHEMBL30152254 | 0.84 | MEN1 (0.51) | MEN1KMT2AMAPTEGFRERBB2 | |
| SCHEMBL3366592 | 0.84 | MEN1 (0.51) | MEN1KMT2AMAPTEGFRERBB2 | |
| SCHEMBL4031174 | 0.83 | MEN1 (0.45) | MEN1KMT2AMAPTEGFRERBB2 | |
| SCHEMBL1406869 | 0.81 | MRGPRX4 (0.54) | MEN1KMT2AMAPTEGFRERBB2 | |
| SCHEMBL29555766 | 0.81 | EGFR (0.59) | MEN1KMT2AMAPTEGFRERBB2 | |
| SCHEMBL30152359 | 0.81 | MAPT (0.49) | MEN1KMT2AMAPTEGFRERBB2 | |
| SCHEMBL4031443 | 0.81 | MEN1 (0.49) | MEN1KMT2AMAPTEGFRERBB2 | |
| SCHEMBL141880 | 0.81 | EGFR (0.59) | MEN1KMT2AMAPTEGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1699798-A4 | DI-SUBSTITUTED PYRROLOTRIAZINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-1699798-A2 | DI-SUBSTITUTED PYRROLOTRIAZINE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2006-09-13 | — | — | EP | disclosed |
| US-7064203-B2 | Di-substituted pyrrolotriazine compounds | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-06-20 | — | — | US | disclosed |
| US-20050197339-A1 | Di-substituted pyrrolotrizine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
| WO-2005065266-A2 | DI-SUBSTITUTED PYRROLOTRIAZINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197339-A1 | Di-substituted pyrrolotrizine compounds | ERBB2, ERBB4, EGFR | TP53 172/4885MEN1 2876/4885KMT2A 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.